Inhibition of E3-ubiquitin ligase HAKAI for treatment of proliferative disorders

摘要

Human HAKAI (hsHAKAI), an E3-ubiquitin ligase, can be inhibited to treat proliferative disorders, such as cancers, dysplasias and hyperplasias. Effective levels of hsHAKAI can be inhibited, for example, using antisense oligonucleotides, ribozymes, interference RNA, and antibodies. Test compounds can be screened for binding to hsHAKAI, for disruption of hsHAKAI-E-cadherin binding, or for inhibition of hsHAKAI enzymatic activity to identify therapeutic compounds for treating proliferative disorders.